This session will consider novel small molecule therapeutic approaches directed at CF relevant drug targets, including delF508-CFTR, epithelial sodium channels & less frequent CFTR mutations. The session provides perspectives from academic & industrial laboratories.
Discuss innovative approaches to restore the expression, stability & function of delF508-CFTR.
Review the challenges of developing rational new therapies for rare CF mutations.
Explain the therapeutic potential for CF lung disease of small molecules that modify ENaC function.